BDBM102348 US10562854, No. A41::US8536181, A41::US9278930, A41

SMILES CC(C)(C)OC(=O)N1CCN(Cc2ccn(Cc3ccc(Cl)cc3)c(=O)c2O)CC1

InChI Key InChIKey=UPJZLOCUUOIMNC-UHFFFAOYSA-N

Data  10 IC50  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 102348   

TargetEgl nine homolog 1(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataIC50:  1.40E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataIC50:  1.66E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataIC50:  1.40E+4nMpH: 7.5Assay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataIC50:  1.66E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataIC50:  1.40E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataIC50:  1.66E+4nMAssay Description:VEGF: HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following ove...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataIC50:  1.40E+4nMAssay Description:Inhibition of human recombinant EGLN-1 using DLDLEALAPYIPADDDFQL as substrate after 20 mins by mass spectrophotometric analysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataEC50:  1.70E+4nMAssay Description:Inhibition of PHD2 in HEK293 cells assessed as VEGF release by immunoassayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataIC50:  1.40E+4nMAssay Description:Inhibition of HIF-PHD2 (unknown origin) expressed in insect Hi5 cells using peptide as substrateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataIC50:  1.40E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Aerpio Therapeutics

US Patent
LigandPNGBDBM102348(US10562854, No. A41 | US8536181, A41 | US9278930, ...)
Affinity DataIC50:  1.66E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent